ViewMind is honored to have been selected in partnership with the Luxembourg Institute of Health to be the recipients of a 1.36 million euro grant awarded by the Luxembourg Ministry of the Economy, the Luxembourg National Research Fund (FNR), and Luxinnovation.

The project aims to clinically validate ViewMind’s technology to study neurocognitive deficiencies in Long COVID patients. 

The long-term consequences to an individual of catching COVID need to be considered and better understood. A study in the Lancet of 234K patients showed 33.6% of individuals suffer neurological impacts 6 months after recovery. Long COVID patients with neurological impacts have elevated levels of neuroinflammation. Neuroinflammation has demonstrated a key role in the pathogenesis of Alzheimer’s disease and other dementias. 

There is a pressing need for these neurocognitive impacts to be better understood with high sensitivity, accessible, non-invasive, affordable solutions that can support evidence-based disease management.